Beijing Biostar Pharmaceuticals Co., Ltd. (Ticker: 2563.HK) is a biotechnology company focused on developing synthetic biology-driven innovative oncology drugs. The company will list its H-shares on the Hong Kong Stock Exchange (HKEX) on October 31, 2024.

The offering is managed by CCB International Capital Limited and China Securities (International) Corporate Finance Company Limited. The company is raising approximately $35.67 million through this IPO, which values it at around $891.50 million.